MITOXANTRONE Side Effects

6782928-0 | B Precursor Type Acute Leukaemia, Bronchopulmonary Aspergillosis, Haematoma, Haemoptysis
on Jun 02, 2010 Female patient from SPAIN , 26 years of age, was diagnosed with relapsing-remitting multiple sclerosis and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: b precursor type acute leukaemia, bronchopulmonary aspergillosis, haematoma, haemoptysis. Mitoxantrone dosage: 12mg/m2, 1 In 1m. During the same period patient was treated with GLATIRAMER ACETATE (View Glatiramer Acetate Review and Glatiramer Acetate Label ).

6780943-4 | Acute Promyelocytic Leukaemia, Cerebral Haemorrhage, Cytogenetic Analysis Abnormal, Fatigue, Pancytopenia, Pyrexia
Patient was taking Mitoxantrone (View Usage). Patient had the following side effects: acute promyelocytic leukaemia, cerebral haemorrhage, cytogenetic analysis abnormal, fatigue, pancytopenia, pyrexia on Jun 02, 2010 from Additional patient health information: Female patient , 52 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Mitoxantrone dosage: 10 Mg/m2, 1 In 1 M. During the same period patient was treated with AZATHIOPRINE (View Azathioprine Review and Azathioprine Label ), INTERFERON BETA 1B (INTERFERON BETA 1B) (View Interferon Beta 1b (interferon Beta-1b) Review and Interferon Beta 1b (interferon Beta-1b) Label ).

6780942-2 | Acute Promyelocytic Leukaemia, Contusion, Oropharyngeal Pain, Pancytopenia, Pyrexia
Adverse event was reported on Jun 02, 2010 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 10 Mg/m2, 1 In 1 M; 10 Mg/m2, 1 In 3 M) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: SPAIN , 23 years of age, After Mitoxantrone was administered, patient had the following side effects: acute promyelocytic leukaemia, contusion, oropharyngeal pain, pancytopenia, pyrexia.

6780941-0 | Acute Promyelocytic Leukaemia, Bleeding Time Prolonged, Haematoma, Pancytopenia
on Jun 02, 2010 Female patient from , 59 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: acute promyelocytic leukaemia, bleeding time prolonged, haematoma, pancytopenia. Mitoxantrone dosage: 10 Mg/m2, 1 In 3 M.


6780920-3 | Acute Promyelocytic Leukaemia, Decreased Appetite, Depression, Haematoma, Lower Respiratory Tract Infection Bacterial, Relapsing-remitting Multiple Sclerosis, Weight Decreased
on Jun 02, 2010 Female patient from , 33 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). Patient had the following side effects: acute promyelocytic leukaemia, decreased appetite, depression (What is depression?), haematoma, lower respiratory tract infection bacterial, relapsing-remitting multiple sclerosis, weight decreased. Mitoxantrone dosage: 10 Mg/m2, 1 In 3 M. Patient was hospitalized.

6776510-9 | Contusion, Gingival Bleeding, Pyrexia
Patient was taking Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: contusion, gingival bleeding, pyrexia on Jun 02, 2010 from SPAIN Additional patient health information: Male patient , 44 years of age, was diagnosed with secondary progressive multiple sclerosis and. Mitoxantrone dosage: 12 Mg/m2, 1 In 1 M.

6756119-3 | Febrile Neutropenia
Adverse event was reported on Jun 03, 2010 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 20.8 Mg Every Day Iv) was diagnosed with acute myeloid leukaemia and. Location: UNITED STATES , 60 years of age, weighting 200.4 lb, Patient experienced the following unwanted or unexpected effects: febrile neutropenia. During the same period patient was treated with ETOPOSIDE (208 Mg Every Day Iv) (View Etoposide Review and Etoposide Label ).

6422021-X | Acute Promyelocytic Leukaemia
on Oct 29, 2009 Female patient from UNITED STATES , 60 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). Patient had the following side effects: acute promyelocytic leukaemia. Mitoxantrone dosage: 12 Mg/m2 Q 3 Months Iv 4/11/07 - First Dose 1/19/09 - Eighth (last) Dose.

6337326-0 | Left Ventricular Dysfunction
on Aug 28, 2009 Female patient from UNITED STATES , 61 years of age, weighting 103.0 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: left ventricular dysfunction. Mitoxantrone dosage: 1 Every 3 Months Iv Drip. During the same period patient was treated with COPAXONE (View Copaxone Review and Copaxone Label ).

6249115-6 | Febrile Neutropenia, Pancytopenia, Septic Shock
Patient was taking Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, pancytopenia, septic shock on Jun 24, 2009 from UNITED STATES Additional patient health information: Male patient , 46 years of age, weighting 176.4 lb, . Mitoxantrone dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6073838-5 | Anoxic Encephalopathy, Brain Injury, Cardiac Disorder, Cardio-respiratory Arrest, Hypoxic Encephalopathy, Leukaemia, Myocardial Infarction, Respiratory Failure
Adverse event was reported on Feb 09, 2009 by a Male patient taking Mitoxantrone (View Usage) (Dosage: ) was diagnosed with acute monocytic leukaemia and. Location: UNITED STATES , 66 years of age, weighting 407.9 lb, Patient had the following side effects: anoxic encephalopathy, brain injury, cardiac disorder, cardio-respiratory arrest, hypoxic encephalopathy, leukaemia, myocardial infarction, respiratory failure. Patient was hospitalized and became disabled.

6023110-4 | Acute Graft Versus Host Disease In Intestine, Acute Myeloid Leukaemia, Pancytopenia
on Dec 09, 2008 Female patient from , 48 years of age, was diagnosed with relapsing-remitting multiple sclerosis and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: acute graft versus host disease in intestine, acute myeloid leukaemia, pancytopenia. Mitoxantrone dosage: 120mg. During the same period patient was treated with AZATHIOPRINE SODIUM (150mg/day) (View Azathioprine Sodium Review and Azathioprine Sodium Label ). Patient was hospitalized.

6005999-8 | Acalculia, Acid-base Balance Disorder Mixed, Anaemia, Brain Oedema, Brain Scan Abnormal, Continuous Haemodiafiltration, Depressed Level Of Consciousness, Dysphasia, Fluid Overload
on Dec 03, 2008 Male patient from AUSTRALIA , 69 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: acalculia, acid-base balance disorder mixed, anaemia, brain oedema, brain scan abnormal, continuous haemodiafiltration, depressed level of consciousness, dysphasia, fluid overload. Mitoxantrone dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), RITUXIMAB (RITUXIMAB) (View Rituximab (rituximab) Review and Rituximab (rituximab) Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), CANDESARTAN CILEXETIL (View Candesartan Cilexetil Review and Candesartan Cilexetil Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ).

5985957-X | Activities Of Daily Living Impaired, Bone Pain, Cerebrovascular Accident, Dysphagia, Ischaemic Cerebral Infarction, Lacunar Infarction
Patient was taking Mitoxantrone (View Usage). Patient had the following side effects: activities of daily living impaired, bone pain, cerebrovascular accident, dysphagia, ischaemic cerebral infarction, lacunar infarction on Dec 05, 2008 from UNITED KINGDOM Additional patient health information: Male patient , 65 years of age, weighting 264.6 lb, was diagnosed with prostate cancer (What is prostate cancer?) and. Mitoxantrone dosage: 24 Mg - Intravenous Nos. During the same period patient was treated with PREDNISONE (10 Mg - Oral) (View Prednisone Review and Prednisone Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), GOSERELIN (View Goserelin Review and Goserelin Label ), ALBUTEROL SULFATE (View Albuterol Sulfate Review and Albuterol Sulfate Label ), FLUTICASONE PROPIONATE (View Fluticasone Propionate Review and Fluticasone Propionate Label ), ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), DOMPERIDONE (View Domperidone Review and Domperidone Label ). Patient was hospitalized.

5935214-2 | Acute Myeloid Leukaemia, Bone Marrow Failure, Pancytopenia, Pyrexia
Adverse event was reported on Oct 17, 2008 by a Male patient taking Mitoxantrone (View Usage) (Dosage: ) was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii stage iv and. Location: ITALY , 75 years of age, After Mitoxantrone was administered, patient had the following side effects: acute myeloid leukaemia, bone marrow failure, pancytopenia, pyrexia. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).

5935211-7 | Acute Graft Versus Host Disease, Acute Myeloid Leukaemia, Pancytopenia
on Oct 17, 2008 Female patient from ITALY , 56 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii stage iv and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, acute myeloid leukaemia, pancytopenia. Mitoxantrone dosage: . During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

5924102-3 | Acute Graft Versus Host Disease In Intestine, Pancytopenia
on Sep 30, 2008 Female patient from FRANCE , 48 years of age, was diagnosed with acute myeloid leukaemia and was treated with Mitoxantrone (View Usage). Patient had the following side effects: acute graft versus host disease in intestine, pancytopenia. Mitoxantrone dosage: 120 Mg;. During the same period patient was treated with AZATHIOPRINE (150 Mg; Daily) (View Azathioprine Review and Azathioprine Label ), INTERFERON BETA 1B (INTERFERON BETA 2B) (PREV.) (View Interferon Beta-1b (interferon Beta-2b) (prev.) Review and Interferon Beta-1b (interferon Beta-2b) (prev.) Label ).

5918307-5 | Acute Promyelocytic Leukaemia, Optic Neuritis
Patient was taking Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: acute promyelocytic leukaemia, optic neuritis on Oct 05, 2008 from UNITED STATES Additional patient health information: Female patient , 54 years of age, was diagnosed with acute promyelocytic leukaemia, multiple sclerosis (What is multiple sclerosis?) and. Mitoxantrone dosage: . During the same period patient was treated with INTERFERON BETA 1A (View Interferon Beta-1a Review and Interferon Beta-1a Label ).

5905868-5 | Acute Myeloid Leukaemia, Borrelia Infection, Central Nervous System Lesion, Condition Aggravated, Demyelination
Adverse event was reported on Oct 01, 2008 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 12m2 Varied Iv Drip) was diagnosed with demyelination and. Location: UNITED STATES , 41 years of age, weighting 195.0 lb, Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, borrelia infection, central nervous system lesion, condition aggravated, demyelination. During the same period patient was treated with ZOFRAN (View Zofran Review and Zofran Label ), IV SOLUMEDROL (View Iv Solumedrol Review and Iv Solumedrol Label ).

5836790-0 | Abdominal Discomfort, Headache, Leukopenia, Nausea, Neutropenia
on Aug 06, 2008 Male patient from UNITED STATES , weighting 145.0 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). Patient had the following side effects: abdominal discomfort, headache (What is headache?), leukopenia, nausea (What is nausea?), neutropenia. Mitoxantrone dosage: . Patient was hospitalized.

5825528-9 | Pulmonary Embolism
on Jul 24, 2008 Male patient from UNITED STATES , 76 years of age, weighting 178.8 lb, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: pulmonary embolism (What is pulmonary embolism?). Mitoxantrone dosage: 12 Mg/m2 - Intravenous Drip. During the same period patient was treated with PREDNISONE (20 Mg) (View Prednisone Review and Prednisone Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), ALBUTEROL SULFATE (View Albuterol Sulfate Review and Albuterol Sulfate Label ), ACETYLSALICYLIC ACID SRT (View Acetylsalicylic Acid Srt Review and Acetylsalicylic Acid Srt Label ), IPRATROPIUM BROMIDE (View Ipratropium Bromide Review and Ipratropium Bromide Label ), PROCHLORPERAZINE EDISYLATE (View Prochlorperazine Edisylate Review and Prochlorperazine Edisylate Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ). Patient was hospitalized.

5755508-3 | Blood Homocysteine Increased, Cerebral Infarction, Cerebrovascular Accident, Dysarthria, Dysphagia, Fatigue, Haemoglobin Decreased, Hypoaesthesia, Leukopenia
Patient was taking Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: blood homocysteine increased, cerebral infarction, cerebrovascular accident, dysarthria, dysphagia, fatigue, haemoglobin decreased, hypoaesthesia, leukopenia on May 30, 2008 from UNITED STATES Additional patient health information: Male patient , 69 years of age, weighting 206.8 lb, was diagnosed with prostate cancer (What is prostate cancer?) and. Mitoxantrone dosage: 12 Mg/m2 Q3w - Intravenous Drip. During the same period patient was treated with PREDNISONE TAB (10 Mg Qd - Oral) (View Prednisone Tab Review and Prednisone Tab Label ), HYDRALAZINE HCL (View Hydralazine Hcl Review and Hydralazine Hcl Label ), NYSTATIN (View Nystatin Review and Nystatin Label ), HYDROCORTISONE (View Hydrocortisone Review and Hydrocortisone Label ), VICODIN (View Vicodin Review and Vicodin Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ), SENNA (View Senna Review and Senna Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

5751459-9 | Acute Promyelocytic Leukaemia, Cellulitis, Marrow Hyperplasia, Pancytopenia
Adverse event was reported on May 15, 2008 by a Male patient taking Mitoxantrone (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 51 years of age, Patient had the following side effects: acute promyelocytic leukaemia, cellulitis (What is cellulitis?), marrow hyperplasia, pancytopenia.

5751458-7 | Acute Promyelocytic Leukaemia, Marrow Hyperplasia, Pancytopenia
on May 15, 2008 Female patient from UNITED STATES , 48 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: acute promyelocytic leukaemia, marrow hyperplasia, pancytopenia. Mitoxantrone dosage: 12 Mg/m2oth.

5738588-0 | Bifascicular Block, Carotid Arteriosclerosis, Dizziness, Electrocardiogram Qrs Complex Prolonged, Feeling Abnormal, Gastrooesophageal Reflux Disease, Left Ventricular Hypertrophy, Syncope
on May 12, 2008 Male patient from UNITED STATES , 85 years of age, weighting 136.2 lb, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: bifascicular block, carotid arteriosclerosis, dizziness (What is dizziness?), electrocardiogram qrs complex prolonged, feeling abnormal, gastrooesophageal reflux disease, left ventricular hypertrophy, syncope. Mitoxantrone dosage: 12 Mg/m2 Q3w - Intravenous Drip. During the same period patient was treated with PREDNISONE TAB (10 Mg Qd Oral) (View Prednisone Tab Review and Prednisone Tab Label ), LEUPROLIDE ACETATE (View Leuprolide Acetate Review and Leuprolide Acetate Label ), PROCHLORPERAZINE EDISYLATE (View Prochlorperazine Edisylate Review and Prochlorperazine Edisylate Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), LORTAB (View Lortab Review and Lortab Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), VITAMIN CAP (View Vitamin Cap Review and Vitamin Cap Label ), VALSARTAN (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5730375-2 | Bradycardia
Patient was taking Mitoxantrone (View Usage). Patient had the following side effects: bradycardia on Apr 23, 2008 from UNITED KINGDOM Additional patient health information: Male patient , child 7 years of age, weighting 50.49 lb, was diagnosed with acute lymphocytic leukaemia recurrent and. Mitoxantrone dosage: 9 Mg Oth Iv. During the same period patient was treated with AMBISOME (View Ambisome Review and Ambisome Label ), ASPARAGINASE (View Asparaginase Review and Asparaginase Label ), DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), SEPTRIN (View Septrin Review and Septrin Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ).

5725930-X | Acute Myeloid Leukaemia, Refusal Of Treatment By Patient
Adverse event was reported on Apr 14, 2008 by a Male patient taking Mitoxantrone (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 42 years of age, After Mitoxantrone was administered, patient had the following side effects: acute myeloid leukaemia, refusal of treatment by patient.

5720594-3 | Bifascicular Block, Carotid Arteriosclerosis, Dizziness, Electrocardiogram Qrs Complex Prolonged, Left Ventricular Hypertrophy, Presyncope
on Apr 25, 2008 Male patient from UNITED STATES , 85 years of age, weighting 136.2 lb, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: bifascicular block, carotid arteriosclerosis, dizziness (What is dizziness?), electrocardiogram qrs complex prolonged, left ventricular hypertrophy, presyncope. Mitoxantrone dosage: 12 Mg/m2 Q3w - Intravenous Drip. During the same period patient was treated with PREDNISONE TAB (10 Mg Qd - Oral) (View Prednisone Tab Review and Prednisone Tab Label ), LEUPROLIDE ACETATE (View Leuprolide Acetate Review and Leuprolide Acetate Label ), PROCHLORPERAZINE EDISYLATE (View Prochlorperazine Edisylate Review and Prochlorperazine Edisylate Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), LORTAB (View Lortab Review and Lortab Label ), IBUPROFEN TABLETS (View Ibuprofen Tablets Review and Ibuprofen Tablets Label ), VITAMIN CAP (View Vitamin Cap Review and Vitamin Cap Label ), VALSARTAN (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5663872-9 | Alanine Aminotransferase Increased, Arrhythmia, Aspartate Aminotransferase Increased, Atrioventricular Block Complete, Bilirubin Conjugated Increased, Blood Albumin Decreased, Blood Bilirubin Increased, Bone Disorder, Bundle Branch Block Right
on Feb 21, 2008 Male patient from CHINA , 74 years of age, weighting 119.0 lb, was diagnosed with prostate cancer metastatic and was treated with Mitoxantrone (View Usage). Patient had the following side effects: alanine aminotransferase increased, arrhythmia (What is arrhythmia?), aspartate aminotransferase increased, atrioventricular block complete, bilirubin conjugated increased, blood albumin decreased, blood bilirubin increased, bone disorder, bundle branch block right. Mitoxantrone dosage: 18 Mg Q3w Iv. During the same period patient was treated with PREDNISONE (10 Mg Po) (View Prednisone Review and Prednisone Label ), GRANISETRON (View Granisetron Review and Granisetron Label ).

5625226-0 | Arrhythmia, Atrioventricular Block Complete, Bundle Branch Block Right, Cardiac Arrest, Hypoxia, Immunodeficiency, Lung Infection, Lung Neoplasm
Patient was taking Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: arrhythmia (What is arrhythmia?), atrioventricular block complete, bundle branch block right, cardiac arrest (What is cardiac arrest?), hypoxia, immunodeficiency, lung infection, lung neoplasm on Jan 25, 2008 from CHINA Additional patient health information: Male patient , 74 years of age, weighting 119.0 lb, was diagnosed with prostate cancer metastatic and. Mitoxantrone dosage: 18 Mg Q3w Iv. During the same period patient was treated with PREDNISONE TAB (10 Mg Po) (View Prednisone Tab Review and Prednisone Tab Label ).

5614887-8 | Anaemia, Bronchitis, Condition Aggravated, Escherichia Infection, Feeling Abnormal, Interstitial Lung Disease, Lung Consolidation, Lung Infection, Lymphadenopathy
Adverse event was reported on Jan 18, 2008 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 20 Mg Q3w Iv) was diagnosed with prostate cancer (What is prostate cancer?) and. Location: CHINA , 71 years of age, weighting 121.3 lb, Patient experienced the following unwanted or unexpected effects: anaemia, bronchitis (What is bronchitis?), condition aggravated, escherichia infection, feeling abnormal, interstitial lung disease, lung consolidation, lung infection, lymphadenopathy. During the same period patient was treated with PREDNISONE TAB (10 Mg Bid Po) (View Prednisone Tab Review and Prednisone Tab Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ).

5593249-6 | Anaemia, Bronchitis, Condition Aggravated, Escherichia Infection, Interstitial Lung Disease, Lobar Pneumonia, Lung Neoplasm, Lymphadenopathy Mediastinal
on Dec 27, 2007 Male patient from CHINA , 71 years of age, weighting 121.3 lb, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Mitoxantrone (View Usage). Patient had the following side effects: anaemia, bronchitis (What is bronchitis?), condition aggravated, escherichia infection, interstitial lung disease, lobar pneumonia, lung neoplasm, lymphadenopathy mediastinal. Mitoxantrone dosage: 20 Mg Q3w Iv. During the same period patient was treated with PREDNISONE (10 Mg Bid Po) (View Prednisone Review and Prednisone Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ).

5592550-X | Pancreatitis Acute
on Jan 03, 2008 Female patient from GERMANY , 48 years of age, was diagnosed with secondary progressive multiple sclerosis and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: pancreatitis acute. Mitoxantrone dosage: 9 Mg/m2 Freq Iv.

5531565-4 | Agitation, Confusional State, Delusion, Dementia, Hallucination, Infection, Insomnia, Malignant Neoplasm Progression, Meningitis
Patient was taking Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: agitation, confusional state, delusion, dementia (What is dementia?), hallucination, infection (What is infection?), insomnia, malignant neoplasm progression, meningitis (What is meningitis?) on Nov 21, 2007 from UNITED STATES Additional patient health information: Male patient , 84 years of age, weighting 107.8 lb, was diagnosed with prostate cancer (What is prostate cancer?) and. Mitoxantrone dosage: 12 Mg/m2 Q3w - Intravenous Nos. During the same period patient was treated with PREDNISONE (10 Mg Qd - Oral) (View Prednisone Review and Prednisone Label ), GLYCERYL TRINITRATE (View Glyceryl Trinitrate Review and Glyceryl Trinitrate Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ), TEMAZEPAM (View Temazepam Review and Temazepam Label ), TRIAMTERENE (View Triamterene Review and Triamterene Label ), METOPROLOL (View Metoprolol Review and Metoprolol Label ), DOCUSATE SODIUM (View Docusate Sodium Review and Docusate Sodium Label ), MEGESTROL (View Megestrol Review and Megestrol Label ). Patient was hospitalized.

5524987-9 | Discomfort, Neutropenic Infection, Pulmonary Fibrosis, Respiratory Failure, White Blood Cell Count Decreased
Adverse event was reported on Nov 01, 2007 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 20 Mg Q3w Iv) was diagnosed with prostate cancer (What is prostate cancer?) and. Location: CHINA , 71 years of age, weighting 121.3 lb, Patient had the following side effects: discomfort, neutropenic infection, pulmonary fibrosis (What is pulmonary fibrosis?), respiratory failure, white blood cell count decreased. During the same period patient was treated with PREDNISONE TAB (10 Mg Bid Po) (View Prednisone Tab Review and Prednisone Tab Label ).

5404973-X | Agitation, Aspergillosis, Cerebral Infarction, Febrile Neutropenia, Hypertension, Hypotension, Lung Infection Pseudomonal, Mucosal Inflammation, Oedema
on Jul 25, 2007 Male patient from UNITED STATES , 67 years of age, was diagnosed with acute myeloid leukaemia and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: agitation, aspergillosis, cerebral infarction, febrile neutropenia, hypertension, hypotension, lung infection pseudomonal, mucosal inflammation, oedema. Mitoxantrone dosage: . During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), CEP 701 (80 Mcg Bid; Po) (View Cep-701 Review and Cep-701 Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

5404714-6 | Diplopia
on May 11, 2007 Male patient from UNITED KINGDOM , 73 years of age, was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: diplopia. Mitoxantrone dosage: 10.5 Mg. During the same period patient was treated with FLUDARABINE PHOSPHATE (20 Mg Po) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CYCLOPHOSPHAMIDE (250 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), MABTHERA. MFR. NOT SPECIFIED (View Mabthera. Mfr. Not Specified Review and Mabthera. Mfr. Not Specified Label ). Patient was hospitalized.

5376676-1 | Calculus Bladder, Urinary Tract Infection, White Blood Cell Count Decreased
Patient was taking Mitoxantrone (View Usage). Patient had the following side effects: calculus bladder, urinary tract infection (What is urinary tract infection?), white blood cell count decreased on Jun 21, 2007 from CHINA Additional patient health information: Male patient , 62 years of age, weighting 154.3 lb, was diagnosed with prostate cancer (What is prostate cancer?) and. Mitoxantrone dosage: 20 Mg Cyc Iv. During the same period patient was treated with PREDNISONE (Qd Po) (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

5369645-9 | Central Line Infection, Condition Aggravated, Febrile Neutropenia, Hypotension, Oxygen Saturation Decreased, Pleural Effusion, Pneumonia
Adverse event was reported on Jun 14, 2007 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 16.7 Mg Qd Iv) was diagnosed with acute myeloid leukaemia and. Location: UNITED STATES , 22 years of age, After Mitoxantrone was administered, patient had the following side effects: central line infection, condition aggravated, febrile neutropenia, hypotension, oxygen saturation decreased, pleural effusion, pneumonia (What is pneumonia?). During the same period patient was treated with CYTARABINE (2090 Mg Qd Iv) (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (209 Mg Qd Iv) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

5363028-3 | Acute Lymphocytic Leukaemia, Hyperlipidaemia, Hypertension, Myocardial Infarction, Pancytopenia
on Jun 04, 2007 Female patient from UNITED STATES , 40 years of age, was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: acute lymphocytic leukaemia, hyperlipidaemia, hypertension, myocardial infarction, pancytopenia. Mitoxantrone dosage: 12 Mg/m2, 1 In 3 Months.

5350665-5 | Pulmonary Alveolar Haemorrhage
on May 29, 2007 Male patient from ITALY , weighting 165.3 lb, was diagnosed with acute myeloid leukaemia and was treated with Mitoxantrone (View Usage). Patient had the following side effects: pulmonary alveolar haemorrhage. Mitoxantrone dosage: 7 Mg/m^2 - 39 Mg. During the same period patient was treated with ETOPOSIDE (100 Mg/m^2 - 180mg For A Cumulative Dose 540 Mg) (View Etoposide Review and Etoposide Label ), ARA C (100 Mg/m^2 1260 Mg) (View Ara-c Review and Ara-c Label ).

5350563-7 | Acute Lymphocytic Leukaemia, Hyperlipidaemia, Hypertension, Myocardial Infarction
Patient was taking Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: acute lymphocytic leukaemia, hyperlipidaemia, hypertension, myocardial infarction on May 21, 2007 from UNITED STATES Additional patient health information: Female patient , 40 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Mitoxantrone dosage: 12mg/m2 Every 3 Months. Patient was hospitalized.

5349773-4 | Pulmonary Alveolar Haemorrhage
Adverse event was reported on May 29, 2007 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 7 Mg/m^2 - 39 Mg) was diagnosed with acute myeloid leukaemia and. Location: ITALY , weighting 165.3 lb, Patient experienced the following unwanted or unexpected effects: pulmonary alveolar haemorrhage. During the same period patient was treated with ETOPOSIDE (100 Mg/m^2 - 180mg For A Cumulative Dose 540 Mg) (View Etoposide Review and Etoposide Label ), ARA C (100 Mg/m^2 1260 Mg) (View Ara-c Review and Ara-c Label ).

5292169-4 | Pulmonary Alveolar Haemorrhage
on Apr 02, 2007 Male patient from ITALY , weighting 165.3 lb, was diagnosed with acute myeloid leukaemia and was treated with Mitoxantrone (View Usage). Patient had the following side effects: pulmonary alveolar haemorrhage. Mitoxantrone dosage: 7 Mg/m^2 - 39 Mg. During the same period patient was treated with ETOPOSIDE (100 Mg/m^2 - 40 Mg) (View Etoposide Review and Etoposide Label ), CYTARABINE (100 Mg/m^2 1260 Mg) (View Cytarabine Review and Cytarabine Label ).

5284402-X | Postoperative Wound Infection, Pyrexia, Seroma
on Mar 30, 2007 Male patient from UNITED STATES , 71 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: postoperative wound infection, pyrexia, seroma. Mitoxantrone dosage: 12mg/m2. During the same period patient was treated with FLUDARABINE (25mg/m2) (View Fludarabine Review and Fludarabine Label ), RITUXAN (View Rituxan Review and Rituxan Label ). Patient was hospitalized.

5281062-9 | Blood Pressure Decreased, Interstitial Lung Disease
Patient was taking Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure decreased, interstitial lung disease on Mar 15, 2007 from UNITED STATES Additional patient health information: Female patient , child 5 years of age, was diagnosed with acute myeloid leukaemia and. Mitoxantrone dosage: 7 Mg, 1 In 1 Days, Intravenous (not Otherwise Specified). During the same period patient was treated with CETIRIZINE HYDROCHLORIDE (View Cetirizine Hydrochloride Review and Cetirizine Hydrochloride Label ), FLUTICASONE PROPIONATE (View Fluticasone Propionate Review and Fluticasone Propionate Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), PERFALGAN (PARACETAMOL) (View Perfalgan (paracetamol) Review and Perfalgan (paracetamol) Label ), LAXOBERON (SODIUM PICOSULFATE) (View Laxoberon (sodium Picosulfate) Review and Laxoberon (sodium Picosulfate) Label ), ROCEPHALIN (CEFTRIAXONE SODIUM) (View Rocephalin (ceftriaxone Sodium) Review and Rocephalin (ceftriaxone Sodium) Label ), LEVOLAC (LACTULOSE) (View Levolac (lactulose) Review and Levolac (lactulose) Label ). Patient was hospitalized.

5239532-5 | Acute Myeloid Leukaemia, Malignant Neoplasm Progression, Prostate Cancer
Adverse event was reported on Jan 29, 2007 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 12 Mg/m2 Q21days Iv) was diagnosed with metastases to bone, prostate cancer metastatic and. Location: FRANCE , 64 years of age, Patient had the following side effects: acute myeloid leukaemia, malignant neoplasm progression, prostate cancer (What is prostate cancer?). During the same period patient was treated with DOCETAXEL (View Docetaxel Review and Docetaxel Label ), IROFULVEN (View Irofulven Review and Irofulven Label ), CAPECITABINE (View Capecitabine Review and Capecitabine Label ).

5237935-6 | Leukopenia, Neutropenia, Pyrexia
on Feb 01, 2007 Female patient from FRANCE , 58 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: leukopenia, neutropenia, pyrexia. Mitoxantrone dosage: 18.84 Mg, 1 In 1 Days, Intravenous (not Otherwise Specified). During the same period patient was treated with BROMAZEPAM (View Bromazepam Review and Bromazepam Label ), ESOMEPRAZOLE MAGNESIUM (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ), ACETAMINOPHEN AND CODEINE PHOSPHATE (View Acetaminophen And Codeine Phosphate Review and Acetaminophen And Codeine Phosphate Label ), TIANEPTINE (View Tianeptine Review and Tianeptine Label ), MACROGOL (View Macrogol Review and Macrogol Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ). Patient was hospitalized.

5235117-5 | Abdominal Distension, Cardiac Failure, Cardiogenic Shock, Cardiotoxicity, Cough, Disseminated Intravascular Coagulation, Dyspnoea, Hypotension
on Jan 29, 2007 Female patient from CANADA , 32 years of age, was diagnosed with relapsing-remitting multiple sclerosis and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal distension, cardiac failure, cardiogenic shock, cardiotoxicity, cough, disseminated intravascular coagulation, dyspnoea, hypotension. Mitoxantrone dosage: 8 Mg/m2 Monthly Unk.

5232288-1 | Acute Promyelocytic Leukaemia, Disseminated Intravascular Coagulation, Fatigue, Gingival Bleeding, Hepatosplenomegaly, Hyperhidrosis, Marrow Hyperplasia
Patient was taking Mitoxantrone (View Usage). Patient had the following side effects: acute promyelocytic leukaemia, disseminated intravascular coagulation, fatigue, gingival bleeding, hepatosplenomegaly, hyperhidrosis, marrow hyperplasia on Jan 23, 2007 from ITALY Additional patient health information: Female patient , 21 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Mitoxantrone dosage: See Image. During the same period patient was treated with INTERFERON BETA (INTERFERON BETA) (View Interferon Beta (interferon Beta) Review and Interferon Beta (interferon Beta) Label ).